Cargando…

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial

BACKGROUND: The benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU), in comparison to allopurinol. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakuma, Masashi, Toyoda, Shigeru, Arikawa, Takuo, Koyabu, Yota, Kato, Toru, Adachi, Taichi, Suwa, Hideaki, Narita, Jun-ichi, Anraku, Koetsu, Ishimura, Kimihiko, Yamauchi, Fumitake, Sato, Yasunori, Inoue, Teruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789120/ https://www.ncbi.nlm.nih.gov/pubmed/35077456 http://dx.doi.org/10.1371/journal.pone.0261445

Ejemplares similares

Usefulness of dual-axis rotational coronary angiography in primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction
por: Suwa, Hideaki, et al.
Publicado: (2020)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Allopurinol for prevention of progression of kidney disease with hyperuricemia
por: Pai, B. H. Santhosh, et al.
Publicado: (2013)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

Evaluation of the Effect of Topiroxostat on Renal Function in Patients with Hyperuricemia: STOP-C Study, a Retrospective Observational Cohort Study
por: Tamiya, Eiji, et al.
Publicado: (2022)

The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia
por: Jalalzadeh, Mojgan, et al.
Publicado: (2012)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019)

Commentary on: The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia
por: Nasri, Hamid
Publicado: (2013)

Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
por: Alghamdi, Youssef Saeed, et al.
Publicado: (2020)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Synergistic Impacts of Alpinia oxyphylla Seed Extract and Allopurinol against Experimental Hyperuricemia
por: Sung, Yoon-Young, et al.
Publicado: (2022)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Allopurinol-induced hypersensitivity syndrome followed by painless thyroiditis in a patient with asymptomatic hyperuricemia
por: Chen, Xiaolin, et al.
Publicado: (2020)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats
por: Kawamorita, Yosuke, et al.
Publicado: (2017)

Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
por: Nakamura, Takashi, et al.
Publicado: (2021)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles—Results from a Population-Based PolSenior Study
por: Winder, Mateusz, et al.
Publicado: (2021)

A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2021)

Prediction of Acute-phase Complications in Patients with Infectious Endocarditis
por: Saito, Fumiya, et al.
Publicado: (2019)

Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
por: Ishikawa, Tomohiko, et al.
Publicado: (2020)

Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population
por: Yasukochi, Yoshiki, et al.
Publicado: (2017)

Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study)
por: Kato, Sawako, et al.
Publicado: (2016)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
por: Hosoya, Tatsuo, et al.
Publicado: (2018)

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
por: Suzuki, Satoshi, et al.
Publicado: (2021)

Identification of four genes as novel susceptibility loci for early-onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia
por: Yamada, Yoshiji, et al.
Publicado: (2018)

Allopurinol induced erythroderma
por: Sharma, Geeta, et al.
Publicado: (2013)

Allopurinol: Sorrow to the marrow
por: Raaju, UR, et al.
Publicado: (2020)

Allopurinol hypersensitivity syndrome
por: Yaseen, Wid, et al.
Publicado: (2023)

Association of serum concentrations of irisin and the adipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients
por: Kaneda, Hiroyuki, et al.
Publicado: (2018)

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2014)

Allopurinol-induced DRESS syndrome
por: Yaylacı, Selcuk, et al.
Publicado: (2012)

Transient hypofibrinogenemia due to allopurinol
por: Yin, ZhiQiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1u15hujcsop4e365rlv8e8pbd6